TCDA GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
TCDA
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Did you know?
Capital expenditures decreased by 94% from FY20 to FY21.
Current Price
$0.11
Profile
Valuation (TTM)
Market Cap$6.27M
P/E-0.05
EV—
P/B28.75
Shares Out58.03M
P/Sales—
Revenue$0.00
EV/EBITDA—
TCDA (TCDA) Quality Analysis
TCDA Profitability
Profitability trend analysis coming soon
TCDA Growth
Growth trend analysis coming soon
TCDA Financial Health
Financial health indicators coming soon
TCDA Quality & Fundamental Analysis
TCDA (TCDA) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ. This quality analysis page evaluates TCDA's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
TCDA has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. and a return on equity (ROE) of -61427.52%. Return on assets (ROA) stands at -79.47%.
The debt-to-equity ratio is 649.28, with a current ratio of 4.94.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether TCDA is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.